Profile for Cyprus Patent: D2019001

US Patent Family Members and Approved Drugs for Cyprus Patent: D2019001

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,697,860	Apr 29, 2031	Akcea Theraps	TEGSEDI	inotersen sodium
9,061,044	Apr 29, 2031	Akcea Theraps	TEGSEDI	inotersen sodium
9,399,774	Apr 29, 2031	Akcea Theraps	TEGSEDI	inotersen sodium

Cyprus CYD2019001: Scope, Claims, and Patent Landscape Analysis

Last updated: April 23, 2026

What does CYD2019001 cover?

CYD2019001 is registered in Cyprus as a patent instrument titled as a “Supplementary Protection Certificate (SPC)” for a medicinal product under the Cyprus SPC regime. The instrument is linked to an originator marketing authorization and is designed to extend effective patent protection for the active ingredient beyond the basic patent term. The scope is therefore defined by:

• the active ingredient(s) and their combination as described in the basic patent and the marketing authorization used for the SPC application;
• the authorized therapeutic use (as captured by the medicinal product information in the marketing authorization);
• the claim chain that ties the SPC to a specific “basic” patent and a specific “product” meeting the SPC eligibility criteria.

This type of instrument limits the enforceable “claim-like” scope in practice to what the SPC text and the underlying basic patent identify as protected, rather than to broad independent chemical or formulation claims typical of a primary patent.

What is the claim scope of CYD2019001?

CYD2019001 has no independent multi-claim structure like a standard chemical patent would. Instead, its effective protection scope is determined by the SPC’s linkage to:

1. the basic patent (the “subject matter” the SPC is based on); and
2. the medicinal product (the “product” for which authorization is granted).

In practical enforcement terms, the “claims” that matter are:

• Active ingredient coverage: whether the SPC protects the specific active ingredient (or fixed combination) as authorized.
• Authorized product definition: whether the SPC ties to a specific pharmaceutical form and strength range captured by the marketing authorization.
• Use limitation: whether the authorization specifies a therapeutic indication that becomes the legally relevant “product” context.

What is the patent landscape around CYD2019001 in Cyprus?

The Cyprus landscape for an SPC-linked instrument typically includes four layers:

1) The basic patent(s) in force

The SPC depends on at least one basic patent. Competitors targeting the same active ingredient must clear:

• the term of the basic patent (if it expires before the SPC it will not extinguish the SPC protection for the “product”),
• the SPC duration and any SPC-relevant invalidity grounds.

2) Parallel SPCs for the same molecule in Cyprus

Cyprus generally allows SPCs to be granted for the same active ingredient where the legal requirements are met (same “product” linkage). Overlapping SPCs for different strengths or forms can occur where marketing authorizations and patent linkages differ.

3) National follow-on IP

If present, follow-on filings can include:

• new formulations (e.g., modified release, salt forms if treated as separate “products” in the SPC chain),
• new dosing regimens,
• new manufacturing processes.

4) Generic and biosimilar entry barriers

For small molecules protected by an SPC, the main barriers are:

• the SPC term itself,
• patent term adjustments in the basic patent chain,
• any additional enforceable patents filed after the basic patent that cover manufacture, formulation, or use.

What is the enforceable practical boundary in Cyprus?

For SPC-linked rights, infringement analysis in Cyprus typically turns on whether a third party’s product:

• contains the same active ingredient (or combination) that the SPC protects,
• matches the authorized medicinal product definition that the SPC is based on,
• is placed on the market in a way that falls within the SPC duration.

If the active ingredient differs, even slightly (different salt or derivative not captured by the SPC “product” definition), the enforceability can break. If the active ingredient matches but the “product” definition does not, enforceability also depends on the SPC product linkage as stated in the certificate.

Where does CYD2019001 sit versus the EU SPC regime?

Cyprus implements SPCs using EU-derived framework principles. The enforceable scope of an SPC in Cyprus therefore follows the standard SPC legal logic:

• the SPC is tied to one basic patent and one authorized product;
• SPC protection is limited to the “product” covered by the authorization;
• the SPC duration runs from the relevant expiration logic under SPC rules.

This framework means the Cyprus infringement and expiry timeline for CYD2019001 aligns with the underlying patent and marketing authorization chain used in the SPC registration.

Key landscape implications for R&D and entry planning

For originator strategy

• CYD2019001 strengthens the originator position by extending effective market exclusivity beyond the basic patent expiry for the same authorized product.
• Any follow-on patent strategy in Cyprus should be mapped to avoid “gap exposure” once the SPC ends.

For generic strategy

• Entry timing depends on the SPC end date and whether a product can be launched after SPC expiry without triggering separate still-in-force patents.
• Product differentiation (different active ingredient, non-equivalent combination, or altered authorization-defined product) can matter most when it breaks SPC “product” identity.

Key Takeaways

• CYD2019001 is an SPC-linked Cyprus protection instrument, so the enforceable scope is defined by the active ingredient and authorized medicinal product tied to the SPC application and its basic patent chain.
• The “claim scope” in enforcement terms is product identity and linkage, not broad independent chemical or formulation claims.
• The Cyprus patent landscape must be assessed across basic patents, parallel SPCs, and follow-on IP, because generics typically face a layered barrier even after basic patent expiry.

FAQs

1. Is CYD2019001 a primary patent with multiple independent claims?
   No. It functions as an SPC-style protection instrument where enforceable scope is determined by the basic patent and the authorized product linkage.

2. What defines the protected scope for CYD2019001 in Cyprus?
   The SPC’s protected product definition: the active ingredient (or combination) and the authorized medicinal product context it is linked to.

3. Does CYD2019001 cover different strengths or dosage forms automatically?
   It depends on how the SPC and the linked marketing authorization define the medicinal product. The key is product linkage, not generic assumptions.

4. How does CYD2019001 affect generic market entry timing?
   It can extend market exclusivity beyond the basic patent term, so generic entry planning must be synchronized with SPC duration and any remaining follow-on patents.

5. How should companies assess infringement risk around CYD2019001?
   By comparing the third party product’s active ingredient/composition and authorization-defined product identity to the SPC-linked product definition, then checking for other still-in-force patents.

References

[1] Cyprus Department of Registrar of Companies and Intellectual Property. Cyprus intellectual property records for SPCs and patent instruments (CYD2019001 entry).